Intensive blood-pressure control in hypertensive chronic kidney disease - sprookjes - yvandenbroek - TriplyDB

Intensive blood-pressure control in hypertensive chronic kidney disease

Intensive blood-pressure control in hypertensive chronic kidney disease

http://www.wikidata.org/entity/Q36872087

about

Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal disease Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans SPRINT: The Study Nephrologists Might Take With a Grain of Salt 2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II-treatments of hypertension Strategies for Controlling Blood Pressure and Reducing Cardiovascular Disease Risk in Patients with Chronic Kidney Disease Updated national and international hypertension guidelines: a review of current recommendations Hypertension and chronic kidney disease: controversies in pathogenesis and treatment Antihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system Addressing the global burden of chronic kidney disease through clinical and translational research Current and Future Treatment of Hypertension in the SPRINT Era Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease.Primary care physicians' familiarity, beliefs, and perceived barriers to practice guidelines in non-diabetic CKD: a survey study.The impact of antihypertensives on kidney disease.Total antihypertensive therapeutic intensity score and its relationship to blood pressure reduction.Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network.Blood pressure and cholesterol control in hypertensive hypercholesterolemic patients: national health and nutrition examination surveys 1988-2010.Metalloproteinases: key and common mediators of multiple GPCRs and candidate therapeutic targets in models of hypertensive cardiac disease.BP, cardiovascular disease, and death in the Folic Acid for Vascular Outcome Reduction in Transplantation trial.Current issues in the management and monitoring of hypertension in chronic kidney disease.Slowing progression of chronic kidney disease Renal failure (chronic)Demographic and health factors associated with enrollment in posttrial studies: the Women's Health Initiative Hormone Therapy Trials.Risk factors for ESRD in individuals with preserved estimated GFR with and without albuminuria: results from the Kidney Early Evaluation Program (KEEP)Association of blood pressure with decline in renal function and time until the start of renal replacement therapy in pre-dialysis patients: a cohort study.Predialysis nephrology care of older patients approaching end-stage renal disease.Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in Spain: the MERENA observational cohort study Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population.Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study.The population genetics of chronic kidney disease: insights from the MYH9-APOL1 locus.African Americans, hypertension and the renin angiotensin system What should be the target blood pressure in patients with chronic kidney disease? Data from the Kidney Early Evaluation Program.Association of high blood pressure with renal insufficiency: role of albuminuria, from NHANES, 1999-2006.Hypertension and kidney disease: what do the data really show?APOL1 risk variants, race, and progression of chronic kidney disease Gene-gene and gene-environment interactions in apolipoprotein L1 gene-associated nephropathy.Ethnicity and second-line antihypertensive medication response in the ASCOT Trial.Cardiorenal syndrome type 4-cardiovascular disease in patients with chronic kidney disease: epidemiology, pathogenesis, and management.Primary care management of chronic kidney disease.Systolic blood pressure and outcomes in stage 3-4 chronic kidney disease patients: evidence from a Taiwanese cohort.

P2860

Q24599916-3556E32B-C6C7-4F27-87B2-5CD45A7DA60B Q24621889-49CCD1B9-58D3-466C-9636-78DC4559DCC2 Q26745888-DEF24518-8B78-4D8B-93CA-10A28738A94C Q26764784-72A9E1CA-ACE1-472D-8C7C-FA3CE4981758 Q26775393-5155941D-0720-4AAE-AA9F-F442EF262555 Q26824589-F16D725B-5B0B-443F-A722-F8574EC5218C Q26851271-53226928-4A68-4EC7-958C-9A2485DA5720 Q26865691-1B8D96B8-1864-45E9-938A-2E2B30B13B2C Q27014158-FD52F505-8ED5-4042-8E1B-71C2A9125094 Q28073270-31DDD86D-8E47-4AB1-8AB8-70BD8E002A4E Q28482437-CB068571-D704-43C7-BCF2-AFD644D77F47 Q30407790-050B6F1C-3758-4B89-B8A1-70DC6E26D571 Q33612080-E5FEB132-AE19-42C3-9644-94BF34296F2C Q33632021-603D111B-1901-4D17-AEFB-9B2521E6A60F Q33668225-6EF310A4-72D6-4598-95EF-AA3816AEC59E Q33789175-2CF68EF5-2A7E-41FD-958E-F4C2EBBB3051 Q33789181-68F7660A-071F-48DF-8357-9B2C125009CC Q33807027-CCBA7ECD-8C86-4DBC-B880-BD859AE83033 Q33814858-1A995781-C7F7-416E-A6FD-C78C589A3766 Q33858915-7AE42552-8124-4A2E-BEAE-36F82143C7BB Q33873241-D444F010-FEA1-4EC6-AD21-4D6321DA0575 Q33910618-E265BC62-9736-47B4-AA46-C595DB22DCAD Q33915401-7F949492-DF53-4F41-995D-2371120F2913 Q33983415-DF51CB38-8ED7-435A-95BB-8ABD0B995D4D Q33991061-62C1B590-2BA7-4E6F-8960-53B25D73CE8B Q34008613-0C64D5E2-6FDC-4C5A-B370-A874F7F23FEA Q34039724-D88DB8C0-07B3-4D7C-A7B8-3043C2534E0B Q34060319-89D6D57C-1B80-453C-AD93-10AF08501A1C Q34078187-1177C18C-5784-43AA-A54E-77D84D53FDB0 Q34182007-2D16090E-B6E1-48B8-AA13-C6D53E2CF02A Q34251854-EFBB5F18-8A00-49B7-9686-FCD1A52D4113 Q34322057-6C79196C-A0AD-4F06-A47E-835183D05F2F Q34339595-BFC8A8B2-1993-40FE-BAA7-EB570EB08BA4 Q34344286-32AB97B6-7872-42B9-AB32-3BE0F4AA9A77 Q34383679-6EDF3198-0A1D-4A7E-90A8-A8951F70BFBD Q34455119-255B21E8-1EFA-4863-A008-BDAB45ED3164 Q34466827-ED714308-E541-419C-8422-14290EE31B1E Q34572435-E7405BB2-AFF9-4166-936E-CBD423FBE80A Q34663541-1626D126-B20C-42D9-ADB8-EB0400BFFACA Q34683689-6A3C033F-05E0-47FB-852B-1EB55037D153

P2860

Intensive blood-pressure control in hypertensive chronic kidney disease

http://www.wikidata.org/entity/Q36872087

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Intensive blood-pressure control in hypertensive chronic kidney disease

@en

type

label

Intensive blood-pressure control in hypertensive chronic kidney disease

@en

prefLabel

Intensive blood-pressure control in hypertensive chronic kidney disease

@en

P1433

Q36872087-4324413C-4F99-4212-A609-9295898AE139

P1476

Q36872087-2389ABD4-5438-4BF7-894C-274A75693704

P2093

Q36872087-0AE21B4E-16BA-4FFB-A94E-641D714636BA

Q36872087-0E6E74DB-3C5D-44DD-914B-EC27F25829DF

Q36872087-1B86E4A0-520F-459C-9CB4-DC2E8DC87023

Q36872087-220CE999-CB8F-4D99-9B08-3451A266CAFF

Q36872087-237B393D-1DE4-4445-B05A-30926277C131

Q36872087-286552FE-CF96-491E-8D0B-8E8841C1895C

Q36872087-2E14EE19-FB1A-4DDB-BF97-E568EE279BC6

Q36872087-3013E7EE-329C-4AAC-B707-2DFFAAB47EFA

Q36872087-33D67A18-70BE-4C07-BA60-72814357BCF4

Q36872087-33F24DE1-CE4F-4563-AEEB-8328CCFB7D5A

P2860

Q36872087-043BECB0-1B39-47C7-AE35-E28E44201D79

Q36872087-071E48C3-1B25-4ECF-84AF-AD8B3B304F4B

Q36872087-1DF4B2A5-3737-438C-ACC2-F7702400AE0B

Q36872087-1E241A77-0BA0-4801-9316-E20DD835CBDC

Q36872087-2B310F7F-1E32-4E1A-853A-72EE86EAB1E3

Q36872087-353D848B-B3A0-4C72-BF8C-84A7ADC731B5

Q36872087-4448DCF3-08DC-4BE7-962D-30C47A388651

Q36872087-54213BB3-4C0C-435E-9F94-B1B28731F2C6

Q36872087-6B3AAC8F-0D3C-427E-A337-CBBB094998AB

Q36872087-6B976986-91CD-4329-8003-954D85D2BE73

P304

Q36872087-49E91E55-1E9C-45C4-A69B-6DC77C0C20D0

P31

Q36872087-043247B2-CCE5-4C12-824E-1DC0B8382464

P356

Q36872087-6766DA17-9853-4A8F-B9B6-7F6713093115

P407

Q36872087-FD783960-42FF-4053-B8DA-B69EF4034B09

P433

Q36872087-5CEC271A-C211-4FC7-93D1-A4ACE726E10B

P478

Q36872087-26ECEA0C-D3D0-40F4-AE4E-5989C4A883C2

P50

Q36872087-EC2399C4-6967-4240-A59D-48C570C0C38E

P577

Q36872087-5C56B2C3-D255-4ED6-A204-E13CA1514D3F

P698

Q36872087-AE07EE1F-6E4D-4444-9E93-28FCA001F495

P932

Q36872087-D3B967BD-ADE2-495E-AE59-D942371DB3C7

P356

P1433

The New England Journal of Medicine

P1476

Intensive blood-pressure control in hypertensive chronic kidney disease

@en

P2093

AASK Collaborative Research Group

http://www.w3.org/2001/XMLSchema#string

Brad C Astor

http://www.w3.org/2001/XMLSchema#string

Edgar R Miller

http://www.w3.org/2001/XMLSchema#string

Francis B Gabbai

http://www.w3.org/2001/XMLSchema#string

Gabriel Contreras

http://www.w3.org/2001/XMLSchema#string

George L Bakris

http://www.w3.org/2001/XMLSchema#string

Jackson T Wright

http://www.w3.org/2001/XMLSchema#string

James P Lash

http://www.w3.org/2001/XMLSchema#string

Janice P Lea

http://www.w3.org/2001/XMLSchema#string

Jeanne Charleston

http://www.w3.org/2001/XMLSchema#string

P2860

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

Treatment blood pressure targets for hypertension

The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1--blood pressure measurement, diagnosis and assessment of risk

Prevalence of chronic kidney disease in the United States

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.

Epidemiology of cardiovascular risk factors in chronic renal disease.

End-stage renal disease in African-American and white men. 16-year MRFIT findings.

Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK).

Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans.

Blood pressure components and the risk for end-stage renal disease and death in chronic kidney disease.

P304

918-929

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA0910975

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

363

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20818902

http://www.w3.org/2001/XMLSchema#string

P932

3662974

http://www.w3.org/2001/XMLSchema#string